Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

Pharmacy Guide

Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.

← Back to all medicines

Tapentadol Aspire 250mg prolonged-release tablets

⚠ This medicine appears to have been discontinued

The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.

If you were prescribed this medicine, other products containing Tapentadol phosphate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.

Active substance: Tapentadol phosphate

Source: electronic medicines compendium (emc)
Official leaflet: Read the PIL on emc

What it is and what it is used for

for The full name of your medicine is 'Tapentadol Aspire 25mg, 50mg, 100mg, 150mg, 200mg or 250mg prolonged release tablets'. It is referred to as 'this medicine' in the rest of this leaflet. This medicine has been prescribed for you for the treatment of severe long-term pain that can only be adequately managed with an opioid painkiller in adults. This medicine contains tapentadol which belongs to a class of medicines called opioids, which are 'pain relievers'. This medicine has been prescribed to you and should not be given to anyone else. Opioids can cause addiction and you may get withdrawal symptoms if you stop taking it suddenly. Your prescriber should have explained how long you will be taking it for and when it is appropriate to stop, how to do this safely.

What you need to know before you take it

e this medicine Do not take this medicine:

  • if you are allergic to tapentadol or any of the other ingredients of this medicine (listed in section 6)
  • if you have asthma or if your breathing is dangerously slow or shallow (respiratory depression, hypercapnia)
  • if you have no bowel movement, as shown by severe constipation and bloating, which may be accompanied by pain or discomfort in the lower stomach
  • if you have poisoning with alcohol, sleeping pills, pain relievers or other psychotropic medicines (medicines that affect mood and emotions) (see 'Other medicines and tapentadol')
  • for acute post-operative pain because of the increased risk of dependency and developing serious breathing problems. If you are going to have an operation, or have just had an operation, please tell the doctor at the hospital if you are taking this medicine. Your doctor may adjust your dose. Warnings and precautions Talk to your doctor or pharmacist before taking this medicine if you:
  • have slow or shallow breathing
  • suffer from increased pressure in the brain or disturbed consciousness, including comas
  • have had a head injury or brain tumours
  • suffer from liver or kidney problems (see 'How to take this medicine')
  • suffer from a pancreatic disease including inflammation of the pancreas (pancreatitis) or disease of the bile duct (biliary tract disease)
  • are taking medicines referred to as mixed opioid agonist/antagonists (e.g., pentazocine, nalbuphine) or partial mu-opioid agonists (e.g. buprenorphine)
  • have a tendency towards epilepsy or fits or if you are taking other medicines known to increase the risk of seizures because the risk of a fit may increase
  • have previously suffered from withdrawal symptoms such as agitation, anxiety, shaking or sweating, when you have stopped taking alcohol or drugs. Tolerance, dependence and addiction This medicine contains tapentadol, which is an opioid. It can cause dependence and/or addiction. This medicine contains tapentadol which is an opioid medicine. Repeated use of opioids can result in the drug being less effective (you become accustomed to it, known as tolerance). Repeated use of Tapentadol can also lead to dependence, abuse and addiction which may result in lifethreatening overdose. The risk of these side effects can increase with a higher dose and longer duration of use. Dependence or addiction can make you feel that you are no longer in control of how much medicine you need to take or how often you need to take it. The risk of becoming dependent or addicted varies from person to person. You may have a greater risk of becoming dependent on or addicted to tapentadol if:
  • you or anyone in your family have ever abused or been dependent on alcohol, prescription medicines or illegal drugs ("addiction")
  • you are a smoker
  • you have ever had problems with your mood (depression, anxiety or a personality disorder) or have been treated by a psychiatrist for other mental illnesses. If you notice any of the following signs whilst taking tapentadol, it could be a sign that you have become dependent or addicted:
  • You need to take the medicine for longer than advised by your doctor.
  • You need to take more than the recommended dose.
  • You might feel that you need to carry on taking your medicine, even when it doesn't help to relieve your pain.
  • You are using the medicine for reasons other than prescribed, for instance, 'to stay calm' or 'help you sleep'.
  • You have made repeated, unsuccessful attempts to quit or control the use of the medicine.
  • When you stop taking the medicine you feel unwell, and you feel better once taking the medicine again ('withdrawal effects'). If you notice any of these signs, speak to your doctor to discuss the best treatment pathway for you, including when it is appropriate to stop and how to stop safely (see section 3, If you stop taking tapentadol). Rarely, increasing the dose of this medicine can make you more sensitive to pain. If this happens, you need to speak to your prescriber about your treatment. Addiction can cause withdrawal symptoms when you stop taking this medicine. Withdrawal symptoms can include restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, loss of appetite, shaking, shivering or sweating. Your prescriber will discuss with you how to gradually reduce your dose before stopping the medicine. It is important that you do not stop taking the medicine suddenly as you will be more likely to experience withdrawal symptoms. Opioids should only be used by those they are prescribed for. Do not give your medicine to anyone else. Taking higher doses or more frequent doses of an opioid, may increase the risk of addiction. Overuse and misuse can lead to overdose and/or death. Sleep-related breathing disorders This medicine can cause sleep-related breathing disorders such as sleep apnoea (breathing pauses during sleep) and sleep related hypoxemia (low oxygen level in the blood). The symptoms can include breathing pauses during sleep, night awakening due to shortness of breath, difficulties to maintain sleep or excessive drowsiness during the day. If you or another person observe these symptoms, contact your doctor. A dose reduction may be considered by your doctor. Other medicines and tapentadol Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Your doctor will tell you which medicines are safe to take with this medicine.
  • The risk of side effects increases if you are taking medicines which may cause convulsions (fits), such as certain antidepressants or antipsychotics. The risk of having a fit may increase if you take this medicine at the same time. Your doctor will tell you whether this medicine is suitable for you.
  • Use of this medicine and sedative medicines such as benzodiazepines or related drugs (certain sleeping pills or tranquillisers (e.g. barbiturates) or pain relievers such as opioids, morphine and codeine (also as cough medicine), antipsychotics, H1-antihistamines, alcohol) increases the risk of drowsiness, difficulties in breathing (respiratory depression), coma and may be life-threatening when taken at the same time as this medicine. Because of this, concomitant use should only be considered when other treatment options are not possible. However, if your doctor does prescribe this medicine together with sedative medicines the dose and duration of concomitant treatment should be limited by your doctor. Please tell your doctor about all sedative medicines you are taking and follow your doctor's dose recommendation closely. It could be helpful to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms.
  • The use of opioids and drugs used to treat epilepsy, nerve pain or anxiety (gabapentin and pregabalin) taken at the same time as tapentadol, increases the risk of opioid overdose, respiratory depression and may be life-threatening.
  • Please tell your doctor if you are taking gabapentin or pregabalin or any sedative medicines, and follow your doctor's dose recommendation closely. It could be helpful to inform friends or relatives to be aware of the signs and symptoms stated above. Contact your doctor when experiencing such symptoms.
  • If you are taking a type of medicine that affects serotonin levels (e.g. certain medicines to treat depression), speak to your doctor before taking this medicine as there have been cases of "serotonin syndrome". Serotonin syndrome is a rare, but life-threatening condition. The signs include involuntary, rhythmic contractions of muscles, including the muscles that control movement of the eye, agitation, excessive sweating, tremor, exaggeration of reflexes, increased muscle tension and body temperature above 38°C. Your doctor can advise you on this.
  • This medicine may not work as well if taken with opioid like medicines (e.g. those containing pentazocine, nalbuphine or buprenorphine). Tell your doctor if you are currently being treated with one of these medicines.
  • Taking this medicine together with other types of medicines referred to as mixed mu-opioid agonist/antagonists (e.g. pentazocine, nalbuphine) or partial mu-opioid agonists (e.g. buprenorphine) has not been studied. It is possible that this medicine will not work as well if given together with one of these medicinal products. Tell your doctor in case you are currently treated with one of these medicinal products.
  • Taking this medicine together with strong inhibitors or inducers (e.g. rifampicin, phenobarbital or St John's Wort) or certain enzymes that are necessary to eliminate tapentadol from your body, may influence how well tapentadol works or may cause side effects, especially when this other medication is started or stopped. Please keep your doctor informed about all medicines you are taking.
  • This medicine should not be taken together with monoamine oxidase inhibitors (MAOIs – certain medicines for the treatment of depression). Tell your doctor if you are taking MAO inhibitors or have taken these during the last 14 days. Please keep your doctor informed about all medicines you are taking. If you use tapentadol together with the below medicines that have anticholinergic effects the risk of side effects may be increased:
  • medicines to treat depression
  • medicines used to treat allergies, travel sickness or nausea (antihistamines or antiemetics)
  • medicines to treat psychiatric disorders (antipsychotics or neuroleptics)
  • muscle relaxants
  • medicines to treat Parkinson's disease. Taking this medicine with food, drink and alcohol Do not drink alcohol whilst you are taking this medicine, because some side effects such as drowsiness may be increased. You can take this medicine with or without food. Pregnancy and breast-feeding If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine: Do not take this medicine:
  • if you are pregnant, unless your doctor has instructed you to do so, if used over prolonged periods during pregnancy, tapentadol may lead to withdrawal symptoms in the newborn baby, which might be life-threatening for the newborn if not recognised and treated by a doctor
  • if you become pregnant during treatment with this medicine. Check with your doctor
  • during childbirth, as it could lead to dangerously slow or shallow breathing (respiratory depression) in the newborn
  • if you are breast-feeding, as it may pass into the breast milk. Driving and using machines This medicine may cause drowsiness, dizziness and blurred vision and may impair your reactions. This may happen especially when you start taking this medicine, when your doctor changes your dosage or when you drink alcohol or take tranquilisers. Please ask your doctor whether it is permitted to drive a car or use machines. This medicine can affect your ability to drive. Do not drive whilst taking this medicine until you know how this medicine affects you. It may be an offence to drive if your ability to drive safely is affected. There is further information for patients who are intending to drive in Great Britain – go to https://www.gov.uk/drug-driving-law.

How to take it

this medicine Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Before starting treatment and regularly during treatment, your doctor will discuss with you what you may expect from using tapentadol, when and how long you need to take it, when to contact your doctor, and when you need to stop it (see also "If you stop taking this medicine" below). Your doctor will change the dose and time between doses of this medicine according to your pain level and your needs. Generally, the lowest pain-relieving dose should be taken. Adults The usual dose is 1 tablet every 12 hours. Total daily doses of this medicine greater than 500mg tapentadol are not recommended. Your doctor may prescribe a different, more appropriate dose or timing of dosing, if this is necessary for you. If you feel that the effect of these tablets is too strong or weak, talk to your doctor or pharmacist. Elderly patients In elderly patients (above 65 years) usually no dose adjustment is necessary. However, the excretion of tapentadol may be delayed in some patients of this age group. If this applies to you, your doctor may adjust your dose or time between doses if required. Patients with liver or kidney disease (insufficiency) Do not take this medicine if you have severe liver or kidney problems. If you have moderate liver problems, your doctor will adjust your dose or time between doses. If you have mild liver problems or mild to moderate kidney problems, a dose adjustment is not required. Children and adolescents This medicine is not suitable for children and adolescents below the age of 18 years. How and when should you take this medicine This medicine is for oral use. Swallow the tablets with a glass of water. You may take the tablets either on an empty stomach or with food. Do not chew, break or crush the tablet, as it may result in overdose due to quick release of tapentadol in your body. The score line is not intended for breaking the tablet. The empty shell of the tablet may not be digested completely and thus be seen in your stool. This should not worry you, since the drug (active substance) of the tablet has already been absorbed in your body and what you see is just the empty shell. How long should you take this medicine Do not take the tablets for longer than your doctor has told you. Your prescriber should have discussed with you, how long the course of tablets will last. They will arrange a plan for stopping treatment. This will outline how to gradually reduce the dose and stop taking the medicine. If you take more of this medicine than you should Taking too much of this medicine may be life-threatening. Immediate medical advice should be sought in the event of an overdose, even if you feel well. Very high doses of this medicine may cause the following:

  • pin-point pupils in the eyes
  • being sick (vomiting)
  • drop in blood pressure
  • fast heartbeat
  • altered consciousness, collapse or deep unconsciousness (coma)
  • epileptic fits
  • dangerously slow or shallow breathing or stopping breathing which may lead to death. If this happens a doctor should be called immediately! If you forget to take this medicine If you forget to take the tablets, your pain is likely to return. Do not take a double dose to make up for a forgotten dose; simply continue taking the tablets as before. If you stop taking this medicine If you interrupt or stop treatment too soon, your pain is likely to return. If you wish to stop treatment, please tell your doctor first before stopping treatment. Generally, there will be no after-effects when treatment is stopped, however, on uncommon occasions, people who have been taking the tablets for some time may feel unwell if they abruptly stop taking them. Symptoms may be:
  • restlessness, watery eyes, runny nose, yawning, sweating, chills, muscle pain and dilated pupils
  • irritability, anxiety, backache, joint pain, weakness, abdominal cramps, difficulty in sleeping, nausea, loss of appetite, vomiting, diarrhoea, and increases in blood pressure, breathing or heart rate. If you experience any of these complaints after stopping treatment, please contact your doctor. You should not suddenly stop taking this medicine unless your doctor tells you to. If your doctor wants you to stop taking your tablets, they will tell you how to do this, this may include a gradual reduction of the dose. If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

Possible side effects

directly via the Yellow Card Scheme at: www.mhra.gov.uk/ yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine.

5

How to store it

this medicine

Store this medicine in a safe and secure storage space, where other people cannot access it. It can cause serious harm and be fatal to people when it has not been prescribed for them. Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date which is stated on the carton and the blister. The expiry date refers to the last day of that month. This medicinal product does not require any special storage conditions. Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

What this medicine looks like and contents of the pack

  • Tapentadol Aspire 25mg prolonged-release tablets are light brown, oblong, biconvex film-coated prolonged release tablets with score lines on both sides.
  • Tapentadol Aspire 50mg prolonged-release tablets are white, oblong, biconvex film-coated prolonged release tablets with score lines on both sides.
  • Tapentadol Aspire 100mg prolonged-release tablets are light yellow, oblong, biconvex film-coated prolonged release tablets with score lines on both sides.
  • Tapentadol Aspire 150mg prolonged-release tablets are light pink, oblong, biconvex film-coated prolonged release tablets with score lines on both sides.
  • Tapentadol Aspire 200mg prolonged-release tablets are yellow, oblong, biconvex film-coated prolonged release tablets with score lines on both sides.
  • Tapentadol Aspire 250mg prolonged-release tablets are reddish brown, oblong, biconvex film-coated prolonged release tablets with score lines on both sides. The tablets are supplied in PVC-PE-PVDC-Aluminium blisters in a cardboard box containing 7, 10, 14, 20, 24, 28, 30, 40, 50, 54, 56, 60, 90 or 100 tablets. Not all pack sizes may be marketed. Marketing Authorisation Holder and Manufacturer Marketing Authorisation Holder: Aspire Pharma Ltd Unit 4, Rotherbrook Court Bedford Road Petersfield Hampshire GU32 3QG United Kingdom Manufacturer: Develco Pharma GmbH Grienmatt 27 DE-79650 Schopfheim Germany This leaflet was last revised in October 2025.

This leaflet is available in formats suitable for the blind and partially sighted. Please contact Aspire Pharma Ltd via telephone: (+44) 01730 231148 or email: [email protected] for more information. 1010583 – P4.1

Artwork for: Product name: Size: PL/PA no: Type: Artwork dimensions: Reason for request: Version no: Date of revision: Colours: Font(s): A/W software: Laetus Code:

Aspire Pharma Limited Tapentadol prolonged-release tablets 25mg/50mg/100mg/150mg/200mg/250mg PL35533/0189-194 Leaflet 200mm x 600mm Text update P4.1 22.10.25 As swatches Strada Pro Indesign CC XXX

Black

Contents of the pack and other information

4 Possible side effects

6

Like all medicines, this medicine can cause side effects, although not everybody gets them. Important side effects or symptoms to look out for and what to do if you are affected:

  • This medicine may cause allergic reactions. Symptoms may be wheeziness, difficulty breathing, swelling of the eyelids, face or lips, or rash or itching, which may cover your whole body.
  • Another serious side effect is a condition where you breathe more slowly or weakly than expected (rare). It mostly occurs in elderly and weak patients. If you are affected by these important side effects, contact a doctor immediately.

What this medicine contains The active ingredient is tapentadol. Each Tapentadol Aspire 25mg prolonged-release tablet contains 25mg tapentadol (as phosphate). Each Tapentadol Aspire 50mg prolonged-release tablet contains 50mg tapentadol (as phosphate). Each Tapentadol Aspire 100mg prolonged-release tablet contains 100mg tapentadol (as phosphate). Each Tapentadol Aspire 150mg prolonged-release tablet contains 150mg tapentadol (as phosphate). Each Tapentadol Aspire 200mg prolonged-release tablet contains 200mg tapentadol (as phosphate). Each Tapentadol Aspire 250mg prolonged-release tablet contains 250mg tapentadol (as phosphate). The other ingredients are:

  • Tablet core: hypromellose, microcrystalline cellulose, colloidal anhydrous silica, magnesium stearate.
  • 25mg tablet coat: hypromellose, glycerol, talc, microcrystalline cellulose, titanium dioxide (E171), red iron oxide (E172), black iron oxide (E172).
  • 50mg tablet coat: hypromellose, glycerol, talc, microcrystalline cellulose, titanium dioxide (E171).
  • 100mg tablet coat: hypromellose, glycerol, talc, microcrystalline cellulose, titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172), black iron oxide (E172).
  • 150mg tablet coat: hypromellose, glycerol, talc, microcrystalline cellulose, titanium dioxide (E171), red iron oxide (E172), black iron oxide (E172).
  • 200mg tablet coat: hypromellose, glycerol, talc, microcrystalline cellulose, titanium dioxide (E171), yellow iron oxide (E172), red iron oxide (E172), black iron oxide (E172).
  • 250mg tablet coat: hypromellose, glycerol, talc, microcrystalline cellulose, titanium dioxide (E171), red iron oxide (E172), black iron oxide (E172).

Other side effects that may occur: Very common (may affect more than 1 in 10 people)

  • feeling sick (nausea)
  • constipation
  • dizziness, drowsiness, headache. Common (may affect up to 1 in 10 people)
  • decreased appetite, anxiety, being sick (vomiting), diarrhoea, indigestion
  • sleep problem, tiredness or exhaustion (fatigue), feeling of weakness, trembling, muscle twitches, shortness of breath
  • feeling depressed, nervousness, restlessness, lack of attention
  • feeling hot (flushing), increased sweating, feeling of body temperature change, dry areas like nostrils, mouth, lips, eyelids, ears, genitals and anus
  • itching, rash
  • water retention (oedema). Uncommon (may affect up to 1 in 100 people)
  • allergic reaction to medicines (including swelling beneath the skin, hives, and in severe cases difficulty breathing, a fall in blood pressure, collapse, or shock)
  • weight loss
  • low awareness of time, place or identity (disorientation), confusion, excitable (agitated), disturbances in perception, abnormal dreams, forgetfulness (memory impairment), mental impairment
  • very happy (euphoria), less consciousness, fainting, sedation, feeling unsteady (balance disorder), difficulty in speaking, numbness
  • abnormal sensations of the skin (e.g. tingling, prickling), skin reactions (hives)
  • abnormal vision
  • faster or slower heartbeat, palpitations, low blood pressure
  • stomach discomfort, delay in passing urine, passing urine more often than usual
  • sexual dysfunction
  • drug withdrawal effects (see 'If you stop taking this medicine')
  • feeling strange, irritable. Rare (may affect up to 1 in 1,000 people)
  • drug dependence
  • thinking abnormal, epileptic fits, near fainting, uncoordinated, feeling drunk or relaxed
  • dangerously slow or shallow breathing (respiratory depression)
  • delayed emptying of the stomach (impaired gastric emptying). Not known (frequency cannot be estimated from the available data)
  • delirium. Drug Withdrawal When you stop taking this medicine, you may experience drug withdrawal symptoms, which include restlessness, difficulty sleeping, irritability, agitation, anxiety, feeling your heartbeat (palpitations), increased blood pressure, feeling or being sick, diarrhoea, shaking, shivering or sweating. How do I know if I am addicted? If you notice any of the following signs whilst taking this medicine, it could be a sign that you have become addicted.
  • You need to take the medicine for longer than advised by your prescriber.
  • You feel you need to use more than the recommended dose.
  • You are using the medicine for reasons other than prescribed.
  • When you stop taking the medicine you feel unwell, and you feel better once taking the medicine again. If you notice any of these signs, it is important you talk to your prescriber. In general, the likelihood of having suicidal thoughts and behaviour is increased in patients suffering from chronic pain. In addition, certain medicines for the treatment of depression (which have an impact on the neurotransmitter system in the brain) may increase this risk, especially at the beginning of treatment. Although tapentadol also affects neurotransmitters, data from human use of tapentadol does not provide evidence for an increased risk. Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report

Frequently asked questions about Tapentadol Aspire 250mg prolonged-release tablets

How do I take Tapentadol Aspire 250mg prolonged-release tablets?

Tapentadol Aspire 250mg prolonged-release tablets comes as tablet containing 250mg. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.

What is the active substance in Tapentadol Aspire 250mg prolonged-release tablets?

The active substance in Tapentadol Aspire 250mg prolonged-release tablets is tapentadol phosphate.

Are there equivalent medicines to Tapentadol Aspire 250mg prolonged-release tablets?

Medicines with the same active substance, strength and form include: Ationdo SR 250mg prolonged release tablets PL 50414/0009, LUPAXIS 250 mg Prolonged-release Tablets, Palexia SR 250 mg prolonged-release tablets. In total there are 5 equivalent products. They are interchangeable only if your prescriber or pharmacist says so.

Where does this information come from?

This leaflet reproduces the patient information leaflet approved for Tapentadol Aspire 250mg prolonged-release tablets, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.

Can I get Tapentadol Aspire 250mg prolonged-release tablets without a prescription?

Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.

About this leaflet

The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.

Medical disclaimer: This page is for information only and does not replace advice from your doctor or pharmacist. Always read the leaflet supplied with your medicine. If you are unwell, call NHS 111; in an emergency, call 999.

Medicines with the same active substance: Tapentadol phosphate (25 medicines)
See every medicine containing this substance, or browse the full A–Z of active substances.
⚕For healthcare professionals — Summary of Product Characteristics (SmPC)Full SmPC: dosage, interactions, contraindications, warnings+
Technical information intended for healthcare professionals (doctors and pharmacists). The Summary of Product Characteristics (SmPC) is the official document approved by the MHRA/EMA. It does not replace the patient leaflet or a doctor’s advice.

4.1. Therapeutic indications

This medicine is indicated for the management of severe chronic pain in adults, which can be adequately managed only with opioid analgesics.

4.2. Posology and method of administration

Prior to starting treatment with opioids, a discussion should be held with patients to put in place a strategy for ending treatment with tapentadol in order to minimise the risk of addiction and drug withdrawal syndrome (see section 4.4).

Posology

The dosing regimen should be individualised according to the severity of pain being treated, the previous treatment experience and the ability to monitor the patient.

This medicine should be taken twice daily, approximately every 12 hours.

Initiation of therapy

Initiation of therapy in patients currently not taking opioid analgesics.

Patients should start treatment with single doses of 50 mg tapentadol as prolonged-release tablet administered twice daily

Initiation of therapy in patients currently taking opioid analgesics

When switching from opioids to this medicine and choosing the initial dose, the nature of the previous medicinal product, administration and the mean daily dose should be taken into account. This may require higher initial doses of Tapentadol SR for patients currently taking opioids compared to those not having taken opioids before initiating therapy with this medicine.

Titration and maintenance

After initiation of therapy the dose should be titrated individually to a level that provides adequate analgesia and minimises undesirable effects under the close supervision of the prescribing physician.

Experience from clinical trials has shown that a titration regimen in increments of 50 mg tapentadol as prolonged-release tablet twice daily every 3 days was appropriate to achieve adequate pain control in most of the patients.

Total daily doses of this medicine greater than 500 mg tapentadol have not yet been studied and are therefore not recommended.

Duration of treatment

Tapentadol should not be used longer than necessary.

Renal Impairment

In patients with mild or moderate renal impairment a dosage adjustment is not required (see section 5.2). This medicine has not been studied in controlled efficacy trials in patients with severe renal impairment, therefore the use in this population is not recommended (see sections 4.4 and 5.2).

Hepatic Impairment

In patients with mild hepatic impairment a dosage adjustment is not required (see section 5.2).

This medicine should be used with caution in patients with moderate hepatic impairment. Treatment in these patients should be initiated at the lowest available dose strength, i.e. 50 mg tapentadol as prolonged-release tablet, and not be administered more frequently than once every 24 hours. At initiation of therapy a daily dose greater than 50 mg tapentadol as prolonged-release tablet is not recommended. Further treatment should reflect maintenance of analgesia with acceptable tolerability (see sections 4.4 and 5.2).

This medicine has not been studied in patients with severe hepatic impairment and therefore, use in this population is not recommended (see sections 4.4 and 5.2).

Elderly patients (persons aged 65 years and over)

In general, a dose adaptation in elderly patients is not required. However, as elderly patients are more likely to have decreased renal and hepatic function, care should be taken in dose selection as recommended (see sections 4.2 and 5.2).

Paediatric Patients

The safety and efficacy of this medicine in children and adolescents below 18 years of age has not yet been established. Therefore, this medicine is not recommended for use in this population.

Method of administration

This medicine has to be taken whole, not divided or chewed, to ensure that the prolonged-release mechanism is maintained.

For oral use.

This medicine should be taken with sufficient liquid. This medicine can be taken with or without food.

The shell (matrix) of the tapentadol tablet may not be digested completely and therefore it can be eliminated and seen in the patient's stool. However, this finding has no clinical relevance, since the active substance of the tablet will have already been absorbed.

Treatment goals and discontinuation

Before initiating treatment with tapentadol, a treatment strategy including treatment duration and treatment goals, and a plan for end of the treatment, should be agreed together with the patient, in accordance with pain management guidelines. During treatment, there should be frequent contact between the physician and the patient to evaluate the need for continued treatment, consider discontinuation and to adjust dosages if needed. When a patient no longer requires therapy with tapentadol, it may be advisable to taper the dose gradually to prevent symptoms of withdrawal. In absence of adequate pain control, the possibility of hyperalgesia, tolerance and progression of underlying disease should be considered (see section 4.4).

4.3. Contraindications

This medicine is contraindicated:

• in patients with hypersensitivity to tapentadol or to any of the excipients listed in section 6.1.

• in situations where active substances with mu-opioid receptor agonist activity are contraindicated, i.e. patients with significant respiratory depression (in unmonitored settings or the absence of resuscitative equipment), and patients with acute or severe bronchial asthma or hypercapnia

• in any patient who has or is suspected of having paralytic ileus

• in patients with acute intoxication with alcohol, hypnotics, centrally acting analgesics, or psychotropic active substances (see section 4.5)

4.4. Special warnings and precautions for use

Tolerance and Opioid Use Disorder (abuse and dependence)

Tolerance, physical and psychological dependence, and opioid use disorder (OUD) may develop upon repeated administration of opioids such as tapentadol. A higher dose and longer duration of opioid treatment can increase the risk of developing OUD. Abuse or intentional misuse of opioids may result in overdose and/or death.

The risk of developing OUD is increased in patients with a personal or a family history (parents or siblings) of substance use disorders (including alcohol use disorder), in current tobacco users or in patients with a personal history of other mental health disorders (e.g. major depression, anxiety and personality disorders).

Before initiating treatment with tapentadol and during the treatment, treatment goals and a discontinuation plan should be agreed with the patient (see section 4.2). Before and during treatment the patient should also be informed about the risks and signs of OUD. If these signs occur, patients should be advised to contact their physician.

Patients will require monitoring for signs of drug-seeking behaviour (e.g. too early requests for refills). This includes the review of concomitant opioids and psycho-active drugs (like benzodiazepines). For patients with signs and symptoms of OUD, consultation with an addiction specialist should be considered.

Do not use for acute post-operative pain owing to the increased risk of persistent post-operative opioid use (PPOU).

Risk from concomitant use of sedating medicinal products such as benzodiazepines or related substances

Concomitant use of this medicine and sedating medicinal products such as benzodiazepines or related substances may result in sedation, respiratory depression, coma and death. Because of these risks, concomitant prescribing with these sedating medicinal products should be reserved for patients for whom alternative treatment options are not possible. If a decision is made to prescribe this medicine concomitantly with sedating medicinal products, the reduction of dose of one or both agents should be considered, and the duration of the concomitant treatment should be as short as possible.

The patients should be followed closely for signs and symptoms of respiratory depression and sedation. In this respect, it is strongly recommended to inform patients and their caregivers to be aware of these symptoms (see section 4.5).

Respiratory Depression

At high doses or in mu-opioid receptor agonist sensitive patients, this medicine may produce dose-related respiratory depression. Therefore, this medicine should be administered with caution to patients with impaired respiratory functions. Alternative non-mu-opioid receptor agonist analgesics should be considered and this medicine should be employed only under careful medical supervision at the lowest effective dose in such patients. If respiratory depression occurs, it should be treated as any mu-opioid receptor agonist-induced respiratory depression (see section 4.9).

Do not use for acute post-operative pain owing to the increased risk of opioid-induced ventilatory impairment (OIVI).

Head Injury and Increased Intracranial Pressure

Tapentadol SR should not be used in patients who may be particularly susceptible to the intracranial effects of carbon dioxide retention such as those with evidence of increased intracranial pressure, impaired consciousness, or coma. Analgesics with mu-opioid receptor agonist activity may obscure the clinical course of patients with head injury. This medicine should be used with caution in patients with head injury and brain tumours.

Seizures

This medicine has not been systematically evaluated in patients with a seizure disorder, and such patients were excluded from clinical trials. However, like other analgesics with mu-opioid agonist activity this medicine is not recommended in patients with a history of a seizure disorder or any condition that would put the patient at risk of seizures. In addition, tapentadol may increase the seizure risk in patients taking other medicinal products that lower the seizure threshold (see section 4.5).

Renal Impairment

This medicine has not been studied in controlled efficacy trials in patients with severe renal impairment, therefore the use in this population is not recommended (see section 4.2 and 5.2).

Hepatic Impairment

Subjects with mild and moderate hepatic impairment showed a 2-fold and 4.5-fold increase in systemic exposure, respectively, compared with subjects with normal hepatic function. Tapentadol SR should be used with caution in patients with moderate hepatic impairment (see section 4.2 and 5.2), especially upon initiation of treatment.

This medicine has not been studied in patients with severe hepatic impairment and therefore, use in this population is not recommended (see sections 4.2 and 5.2).

Use in Pancreatic/Biliary Tract Disease

Active substances with mu-opioid receptor agonist activity may cause spasm of the sphincter of Oddi. this medicine should be used with caution in patients with biliary tract disease, including acute pancreatitis.

Sleep-related breathing disorders

Opioids can cause sleep-related breathing disorders including central sleep apnoea (CSA) and sleep-related hypoxemia. Opioid use increases the risk of CSA in a dose-dependent fashion. In patients who present with CSA, consider decreasing the total opioid dosage.

Mixed opioid agonists/antagonists

Care should be taken when combining this medicine with mixed mu-opioid agonist/antagonists (like pentazocine, nalbuphine) or partial mu-opioid agonists (like buprenorphine). In patients maintained on buprenorphine for the treatment of opioid dependence, alternative treatment options (like e.g. temporary buprenorphine discontinuation) should be considered, if administration of full mu-agonists (like tapentadol) becomes necessary in acute pain situations. On combined use with buprenorphine, higher dose requirements for full mu-receptor agonists have been reported and close monitoring of adverse events such as respiratory depression is required in such circumstances.

4.5. Interaction with other medicinal products and other forms of interaction

Centrally-acting medicinal products/central nervous system (CNS) depressants, including alcohol and CNS depressant narcotic drugs

The concomitant use of Tapentadol with sedating medicinal products such as benzodiazepines or other respiratory or CNS depressants (other opioids, antitussives or substitution treatments, barbiturates, antipsychotics, H1-antihistamines, alcohol) increases the risk of sedation, respiratory depression, coma and death because of additive CNS depressant effect. Therefore, when a combined therapy of Tapentadol SR with a respiratory or CNS depressant is contemplated, the reduction of the dose of one or both agents should be considered and the duration of the concomitant use should be limited (see section 4.4). The concomitant use of opioids and gabapentinoids (gabapentin and pregabalin) increases the risk of opioid overdose, respiratory depression and death.

Mixed opioid agonists/antagonists

Care should be taken when combining his medicine with mixed mu-opioid agonist/antagonists (like pentazocine, nalbuphine) or partial mu-opioid agonists (like buprenorphine) (see also section 4.4).

This medicine can induce convulsions and increase the potential for selective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, antipsychotics and other medicinal products that lower the seizure threshold to cause convulsions.

There have been reports of serotonin syndrome in a temporal connection with the therapeutic use of tapentadol in combination with serotoninergic medicinal products such as selective serotonin re-uptake inhibitors (SSRIs), serotonin-norepinephrine reuptake inhibitors (SNRIs) and tricyclic antidepressants.

Serotonin syndrome is likely when one of the following is observed:

• Spontaneous clonus

• Inducible or ocular clonus with agitation or diaphoresis

• Tremor and hyperreflexia

• Hypertonia and body temperature > 38°C and inducible ocular clonus.

Withdrawal of the serotoninergic medicinal products usually brings about a rapid improvement. Treatment depends on the nature and severity of the symptoms.

The major elimination pathway for tapentadol is conjugation with glucuronic acid mediated via uridine diphosphate transferase (UGT) mainly UGT1A6, UGT1A9 and UGT2B7 isoforms. Thus, concomitant administration with strong inhibitors of these isoenzymes (e.g. ketoconazole, fluconazole, meclofenamic acid) may lead to increased systemic exposure of tapentadol (see section 5.2).

For patients on tapentadol treatment, caution should be exercised if concomitant drug administration of strong enzyme inducing drugs (e.g. rifampicin, phenobarbital, St John's Wort (hypericum perforatum) starts or stops, since this may lead to decreased efficacy or risk for adverse effects, respectively.

Treatment with this medicine should be avoided in patients who are receiving monoamine oxidase (MAO) inhibitors or who have taken them within the last 14 days due to potential additive effects on synaptic noradrenaline concentrations which may result in adverse cardiovascular events, such as hypertensive crisis.

Anticholinergics

Concomitant administration of tapentadol with anticholinergics or medications with anticholinergic activity (e.g. tricyclic antidepressants, antihistamines, antipsychotics, muscle relaxants, anti-Parkinson drugs) may result in increased anticholinergic adverse effects.

4.6. Fertility, pregnancy and lactation

Pregnancy

There is a very limited amount of data from the use in pregnant women.

Studies in animals have not shown teratogenic effects. However, delayed development and embryotoxicity were observed at doses resulting in exaggerated pharmacology (mu-opioid related CNS effects related to dosing above the therapeutic range). Effects on the postnatal development were already observed at the maternal NOAEL (see section 5.3).

This medicine should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus. Regular use during pregnancy may cause drug dependence in the foetus, leading to withdrawal symptoms in the neonate Neonatal opioid withdrawal syndrome can be life-threatening if not recognised and treated. An antidote for the newborn should be readily available. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

Labour and Delivery

The effect of tapentadol on labour and delivery in humans is unknown. This medicine is not recommended for use in women during and immediately before labour and delivery. Due to the mu-opioid receptor agonist activity of tapentadol, new-born infants whose mothers have been taking tapentadol should be monitored for respiratory depression. Administration during labour may depress respiration in the neonate and an antidote for the child should be readily available.

Breast-feeding

There is no information on the excretion of tapentadol in human milk. From a study in rat pups suckled by dams dosed with tapentadol it was concluded that tapentadol is excreted via milk (see section 5.3). Therefore, a risk to the suckling child cannot be excluded.

Administration to nursing women is not recommended as tapentadol may be secreted in breast milk and may cause respiratory depression in the infant. This medicine should not be used during breast feeding.

Fertility

No human data on the effect of This medicine on fertility are available. In a fertility and early embryonic development study, no effects on reproductive parameters were observed in male or female rats (see section 5.3).

4.7. Effects on ability to drive and use machines

This medicine may have major influence on the ability to drive and use machines, because it may adversely affect central nervous system functions (see section 4.8). This has to be expected especially at the beginning of treatment, when any change of dosage occur as well as in connection with the use of alcohol or tranquilisers (see section 4.4). Patients should be cautioned as to whether driving or use of machines is permitted.

This medicine can impair cognitive function and can affect a patient's ability to drive safely. When prescribing this medicine, patients should be told:

• The medicine is likely to affect your ability to drive

• Do not drive until you know how the medicine affects you

• It is an offence to drive if you are unfit to drive

• However, you would not be committing an offence (called 'statutory defence') if:

- The medicine has been prescribed to treat a medical or dental problem and

- You have taken it according to the instructions given by the prescriber and in the information provided with the medicine and

- It was not affecting your ability to drive safely.

4.8. Undesirable effects

The adverse drug reactions that were experienced by patients in the placebo controlled trials performed with this medicine were predominantly of mild and moderate severity. The most frequent adverse drug reactions were in the gastrointestinal and central nervous system (nausea, dizziness, constipation, headache and somnolence).

The table below lists adverse drug reactions that were identified from clinical trials performed with this medicine and from post-marketing environment. They are listed by class and frequency. Frequencies are defined as very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare ((≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data).

ADVERSE DRUG REACTIONS

System Organ Class

Frequency

Very common

Common

Uncommon

Rare

Unknown

Immune system disorders

Drug hypersensitivity*

Metabolism and nutrition disorders

Decreased appetite

Weight decreased

Psychiatric disorders

Anxiety, Depressed mood, Sleep disorder, Nervousness, Restlessness

Disorientation, Confusional state, Agitation, Perception disturbances, Abnormal dreams, Euphoric mood

Thinking Abnormal, Drug Dependence (see section 4.4)

Delirium**

Nervous system disorders

Dizziness, Somnolence, Headache

Disturbance in attention, Tremor, Muscle contractions involuntary

Depressed level of consciousness, Memory impairment, Mental impairment, Syncope, Sedation, Balance disorder, Dysarthria, Hypoaesthesia, Paraesthesia

Convulsion, Presyncope, Coordination abnormal

Eye disorders

Visual disturbance

Cardiac disorders

Heart rate increased, Heart rate decreased, Palpitations

Vascular disorders

Flushing

Blood pressure decreased

Respiratory, thoracic and mediastinal disorders

Dyspnoea

Respiratory depression

Gastrointestinal disorders

Nausea, Constipation

Vomiting, Diarrhoea, Dyspepsia

Abdominal discomfort

Impaired gastric emptying

Skin and subcutaneous tissue disorders

Pruritus, Hyperhidrosis, Rash

Urticaria

Renal and urinary disorders

Urinary hesitation, Pollakiuria

Reproductive system and breast disorders

Sexual dysfunction

General disorders and administration site conditions

Asthenia, Fatigue, Feeling of body temperature change, Mucosal dryness, Oedema

Drug withdrawal syndrome, Feeling abnormal, Irritability

Feeling drunk, Feeling of relaxation

* Post-marketing rare events of angioedema, anaphylaxis and anaphylactic shock have been reported.

** Post marketing cases of delirium were observed in patients with additional risk factors such as cancer and advanced age.

Clinical trials performed with this medicine with patient exposure up to 1 year have shown little evidence of withdrawal symptoms upon abrupt discontinuations and these were generally classified as mild, when they occurred. Nevertheless, physicians should be vigilant for symptoms of withdrawal (see section 4.2) and treat patients accordingly should they occur.

The risk of suicidal ideation and suicides committed is known to be higher in patients suffering from chronic pain. In addition, substances with a pronounced influence on the monoaminergic system have been associated with an increased risk of suicidality in patients suffering from depression, especially at the beginning of treatment. For tapentadol data from clinical trials and post-marketing reports do not provide evidence for an increased risk.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

4.9. Overdose

Patients should be informed of the signs and symptoms of overdose and to ensure that family and friends are also aware of these signs and to seek immediate medical help if they occur.

Symptoms

Human experience with overdose of tapentadol is limited. Preclinical data suggest that symptoms similar to those of other centrally acting analgesics with muopioid receptor agonist activity are to be expected upon intoxication with tapentadol. In principle, these symptoms include, referring to the clinical setting, in particular miosis, vomiting, cardiovascular collapse, consciousness disorders up to coma, convulsions and respiratory depression up to respiratory arrest that may be fatal.

Management

Management of overdose should be focused on treating symptoms of mu-opioid agonism. Primary attention should be given to re-establishment of a patent airway and institution of assisted or controlled ventilation when overdose of tapentadol is suspected.

Pure opioid receptor antagonists such as naloxone are specific antidotes to respiratory depression resulting from opioid overdose. Respiratory depression following an overdose may outlast the duration of action of the opioid receptor antagonist. Administration of an opioid receptor antagonist is not a substitute for continuous monitoring of airway, breathing, and circulation following an opioid overdose. If the response to opioid receptor antagonists is suboptimal or only brief in nature, an additional dose of antagonist (e.g. naloxone) should be administered as directed by the manufacturer of the product.

Gastrointestinal decontamination may be considered in order to eliminate unabsorbed active substance. Gastrointestinal decontamination with activated charcoal or by gastric lavage may be considered within 2 hours after intake. Before attempting gastrointestinal decontamination, care should be taken to secure the airway.

💬 Ask about this leaflet

Ask anything about Tapentadol Aspire 250mg prolonged-release tablets. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.

Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.

Pharmacies in major towns and cities — see the list
Pharmacies by county and region — see the full list

Browse all 2,009 towns and cities →